A comprehensive review on hypertensive disorders of pregnancy: risk stratification, predictors and preventive strategies

Sadaf Nausheen; Reena Wani; Aishwarya Nichani

doi:10.18203/2320-1770.ijrcog20264041

Authors

Sadaf Nausheen Department of Obstetrics and Gynecology, HBTMC and Dr RNMCH, Mumbai, Maharashtra, India
Reena Wani Department of Obstetrics and Gynecology, HBTMC and Dr RNMCH, Mumbai, Maharashtra, India
Aishwarya Nichani Department of Obstetrics and Gynecology, HBTMC and Dr RNMCH, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20264041

Keywords:

Pre-eclampsia, Hypertensive disorders of pregnancy, Risk stratification, Gestosis score, Aspirin, Calcium, Placental growth factor, Mean arterial pressure

Abstract

Hypertensive disorders of pregnancy (HDP), particularly pre-eclampsia, are important causes of maternal and perinatal morbidity and mortality. Because effective prevention must begin before clinical disease is established, antenatal care should include early risk assessment and timely initiation of evidence-based prophylaxis. Pre-eclampsia is a heterogeneous, multisystem disorder in which abnormal placentation and placental stress contribute to an imbalance between pro-angiogenic and anti-angiogenic factors, systemic endothelial dysfunction, and end-organ injury. This review summarises the pathophysiology of pre-eclampsia; examines clinical risk assessment, the HDP-Gestosis Score, mean arterial pressure (MAP), uterine artery Doppler and angiogenic biomarkers; and compares key recommendations from the World Health Organization (WHO) and the NICE/RCOG clinical framework. Low-dose aspirin is recommended for pregnant women at increased risk, with dose and timing determined by the applicable guideline and local protocol. Calcium supplementation is recommended by WHO in populations with low dietary calcium intake. Combined clinical and first-trimester multimarker screening can improve identification of pregnancies at risk of preterm pre-eclampsia, but no screening test replaces ongoing blood-pressure assessment and clinical surveillance. Implementation should prioritise validated tools, clear referral pathways, equitable access to antenatal care and accurate counselling.

References

Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631–44.

Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33.

Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24–43.

American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237–60.

Redman CWG, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–4.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–83.

Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of angiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123(24):2856–69.

National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline NG133. London: NICE; 2019. Updated 2023. Available at: https://www.nice.org.uk/guidance/ng133.Accessed on 12 August 2026

World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World Health Organization; 2011.

Gupta M, Yadav P, Yaqoob F. A prospective study to determine the predictive ability of HDP-Gestosis Score for the development of pre-eclampsia. J Obstet Gynaecol India. 2022;72(6):485–91.

Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–22.

Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(4):492–5.

Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1–33.

World Health Organization. WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia. Geneva: World Health Organization; 2021. Available at: https://www.who.int/publications/i/item/9789240037540. Accessed on 12 August 2026

World Health Organization. WHO recommendation: calcium supplementation during pregnancy for prevention of pre-eclampsia and its complications. Geneva: World Health Organization; 2018. Available at: https://www.who.int/publications/i/item/9789241550451, Accessed on 12 August 2026.